Liso-cel is not indicated for patients with primary lymphoma of the central nervous system.
June 28, 2022 | | Reading time: 4 minutes
Large B-cell lymphoma is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. Photo: Shutterstock.
Lisocabtagene maraleucel, also known as Liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed large B-cell lymphoma or refractory (r/r LBCL).
This expanded indication is based on findings from the pivotal phase 3 TRANSFORM study, which showed significant and clinically meaningful improvements with CD19-directed chimeric antigen receptor T-cell immunotherapy compared with salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant. The last course of treatment had been the standard of care for more than 2 decades.
Data from the global, randomized, multicenter TRANSFORM study, as reported in December 2021 at the annual meeting of the American Society of Hematologyshowed that second-line treatment with lisa-cel in 92 patients with LBCL r/r within 12 months of first-line therapy, compared with 92 patients receiving standard-of-care therapy, was associated with a highly significant improvement statistically and clinically in event-free survival (10.1 vs. 2.3 months; hazard ratio, 0.349), complete response rate (66% vs. 39%), and progression-free survival ( 14.8 vs. 5.7 months, HR, 0.406).
There was also a positive trend in overall survival (HR, 0.509 with a median follow-up of 6.2 months). No new safety signals for lisa-cel were detected in the second-line environment.
Liso-cel was initially approved in February 2021 for the treatment of adults with LBCL, including diffuse unspecified LBCL (including DLBCL arising from a lymphoma indolent), high-grade B-cell lymphomathe lymphoma primary mediastinal large B cell and lymphoma follicular lymphoma grade 3B, which have:
Disease refractory to first-line chemoimmunotherapy or relapsed within 12 months after first-line chemoimmunotherapy.
Disease refractory to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age.
Smooth-cel is not indicated for the treatment of patients with primary central nervous system lymphoma.
In February 2022, the FDA granted priority review status to a Supplemental Biologics License Application (sBLA) from Bristol-Myers Squibb, based on data from the TRANSFORM study, to expand the indication to include use after therapy failure From first line.
The agent “now has the potential to be a new standard of care for patients after failure of first-line therapy, offering significantly better outcomes beyond the current mainstay of care,” said Anne Kerber, senior vice president of drug development. BMS cell therapy.
The European Medicines Agency has also validated a type II variation request for the extension of the indication for lisa-cel in this context. Validation of the application “confirms that the submission is complete and begins the EMA’s centralized review procedure,” BMS announced in a June 20, 2022 press release.
Liso-cel, which has been available only through a restricted program under a risk assessment and mitigation strategy, includes a boxed warning about the risk of cytokine release syndrome (CRS) and neurological toxicities.
The warning states that lisa-cel should not be given to patients with active infection or inflammatory disorders, and that severe or life-threatening CRS should be treated with tocilizumab with or without corticosteroids.
Patients should also be monitored for neurological events after treatment with Lyso-cel, and supportive care and/or corticosteroids administered as needed.
Source consulted here.